Seminars in Hematology
Volume 43 , Pages S2-S10 , April 2006

Pentostatin for the Treatment of Indolent Lymphoproliferative Disorders

  • Anthony D. Ho

      Affiliations

    • Corresponding Author InformationAddress correspondence to Anthony D. Ho, MD, Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
    • ,
  • Manfred Hensel

References 

  1. Ho AD , Knauf W , Ganeshaguru K , Hunstein W , Hoffbrand AV . Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia . Hematol Oncol . 1987;5:9–17
  2. Giblett ER , Anderson JE , Cohen F , Pollara B , Meuwissen HJ . Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity . Lancet . 1972;2:1067–1069
  3. Giblett ER , Ammann AJ , Wara DW , Sandman R , Diamond LK . Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity . Lancet . 1975;1:1010–1013
  4. Biggar WD , Giblett ER , Ozere RL , Grover BD . A new form of nucleoside phosphorylase deficiency in two brothers with defective T-cell function . J Pediatr . 1978;92:354–357
  5. Barton R , Martiniuk F , Hirschhorn R , Goldschneider I . The distribution of adenosine deaminase among lymphocyte populations in the rat . J Immunol . 1979;122:216–220
  6. Chechik BE , Schrader WP , Minowada J . An immunomorphologic study of adenosine deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines . J Immunol . 1981;126:1003–1007
  7. Tung R , Silber R , Quagliata F , Conklyn M , Gottesman J , Hirschhorn R . Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations . J Clin Invest . 1976;57:756–761
  8. Ganeshaguru K , Lee N , Llewellin P , Prentice HG , Hoffbrand AV , Catovsky D , et al.   Adenosine deaminase concentrations in leukaemia and lymphoma (Relation to cell phenotypes) . Leuk Res . 1981;5:215–222
  9. Ho AD , Ganeshaguru K . Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors . Klin Wochenschr . 1988;66:467–474
  10. Cohen A , Hirschhorn R , Horowitz SD , Rubinstein A , Polmar SH , Hong R , et al.   Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency . Proc Natl Acad Sci U S A . 1978;75:472–476
  11. Hershfield MS , Kredich NM . Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation . Proc Natl Acad Sci U S A . 1980;77:4292–4296
  12. Hershfield MS , Kredich NM , Koller CA , Mitchell BS , Kurtzberg J , Kinney TR , et al.   S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2′-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine . Cancer Res . 1983;43:3451–3458
  13. Ho AD , Ganeshaguru K , Knauf WU , Dietz G , Trede I , Hunstein W , et al.   Clinical response to deoxycoformycin in chronic lymphoid neoplasms and biochemical changes in circulating malignant cells in vivo . Blood . 1988;72:1884–1890
  14. Ganeshaguru K , Ho AD , Piga A , Catovsky D , Hoffbrand AV . Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias . Leuk Res . 1987;11:941–945
  15. Gelfand EW , Lee JJ , Dosch HM . Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function . Proc Natl Acad Sci U S A . 1979;76:1998–2002
  16. Woo PWK , Dion HW , Lange SM , Dahl LF , Durham LJ . A novel adenosine and araA deaminase inhibitor, (R)-3-(2-deoxy-β-D-Erythro-pento-furanosyl)-3,6,7,8-tetra-hydroimidazo (4,5-d) (1,3) diazepin-8-ol . J Heterocyclic Chem . 1974;11:641–643
  17. Agarwal RP , Spector T , Parks REJ . Inhibition of adenosine deaminase by various inhibitors . Biochem Pharmacol . 1977;26:359–367
  18. Poplack DG , Sallan SE , Rivera G , Holcenberg J , Murphy SB , Blatt J , et al.   Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia . Cancer Res . 1981;41:3343–3346
  19. Prentice HG , Smyth JF , Ganeshaguru K , Wonke B , Bradstock KF , Janossy G , et al.   Remission induction with adenosine-deaminase inhibitor 2′-deoxycoformycin in Thy-lymphoblastic leukaemia . Lancet . 1980;2:170–172
  20. Prentice HG , Russell NH , Lee N , Ganeshaguru K , Blacklock H , Piga A , et al.   Therapeutic selectivity of and predication of response to 2′-deoxycoformycin in acute leukaemia . Lancet . 1981;2:1250–1254
  21. Smyth JF , Paine RM , Jackman AL , Harrap KR , Chassin MM , Adamson RH , et al.   The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin . Cancer Chemother Pharmacol . 1980;5:93–101
  22. Grever MR , Siaw MF , Jacob WF , Neidhart JA , Miser JS , Coleman MS , et al.   The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy . Blood . 1981;57:406–417
  23. Grever MR , Leiby JM , Kraut EH , Wilson HE , Neidhart JA , Wall RL , et al.   Low-dose deoxycoformycin in lymphoid malignancy . J Clin Oncol . 1985;3:1196–1201
  24. Spiers AS , Ruckdeschel JC , Horton J . Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms . Scand J Haematol . 1984;32:130–134
  25. Ho AD , Thaler J , Stryckmans P , Coiffier B , Luciani M , Sonneveld P , et al.   Pentostatin in refractory chronic lymphocytic leukemia (A phase II trial of the European Organization for Research and Treatment of Cancer) . J Natl Cancer Inst . 1990;82:1416–1420
  26. Seto S , Carrera CJ , Kubota M , Wasson DB , Carson DA . Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes . J Clin Invest . 1985;75:377–383
  27. Siaw MF , Coleman MS . In vitro metabolism of deoxycoformycin in human T lymphoblastoid cells. Phosphorylation of deoxycoformycin and incorporation into cellular DNA . J Biol Chem . 1984;259:9426–9433
  28. Polliack A . Hairy cell leukemia (Biology, clinical diagnosis, unusual manifestations and associated disorders) . Rev Clin Exp Hematol . 2002;6:366–388
  29. Quesada JR , Reuben J , Manning JT , Hersh EM , Gutterman JU . Alpha interferon for induction of remission in hairy-cell leukemia . N Engl J Med . 1984;310:15–18
  30. Ratain MJ , Golomb HM , Vardiman JW , Vokes EE , Jacobs RH , Daly K . Treatment of hairy cell leukemia with recombinant alpha 2 interferon . Blood . 1985;65:644–648
  31. Golomb HM , Jacobs A , Fefer A , Ozer H , Thompson J , Portlock C , et al.   Alpha-2 interferon therapy of hairy-cell leukemia (A multicenter study of 64 patients) . J Clin Oncol . 1986;4:900–905
  32. Ho AD , Thaler J , Mandelli F , Lauria F , Zittoun R , Willemze R , et al.  The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group   Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha . J Clin Oncol . 1989;7:1533–1538
  33. Kraut EH , Bouroncle BA , Grever MR . Pentostatin in the treatment of advanced hairy cell leukemia . J Clin Oncol . 1989;7:168–172
  34. Cassileth PA , Cheuvart B , Spiers AS , Harrington DP , Cummings FJ , Neiman RS , et al.   Pentostatin induces durable remissions in hairy cell leukemia . J Clin Oncol . 1991;9:243–246
  35. Johnston JB , Eisenhauer E , Corbett WE , Scott JG , Zaentz SD . Efficacy of 2′-deoxycoformycin in hairy-cell leukemia (A study of the National Cancer Institute of Canada Clinical Trials Group) . J Natl Cancer Inst . 1988;80:765–769
  36. Golomb HM , Dodge R , Mick R , Budman D , Hutchison R , Horning SJ , et al.   Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon (A report of CALGB study 8515) . Leukemia . 1994;8:2037–2040
  37. Grever M , Kopecky K , Foucar MK , Head D , Bennett JM , Hutchison RE , et al.   Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia (An intergroup study) . J Clin Oncol . 1995;13:974–982
  38. Flinn IW , Kopecky KJ , Foucar MK , Head D , Bennett JM , Hutchison R , et al.   Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin . Blood . 2000;96:2981–2986
  39. Goodman GR , Burian C , Koziol JA , Saven A . Extended follow-up of patients with hairy cell leukemia after treatment with cladribine . J Clin Oncol . 2003;21:891–896
  40. Saven A , Burian C , Koziol JA , Piro LD . Long-term follow-up of patients with hairy cell leukemia after cladribine treatment . Blood . 1998;92:1918–1926
  41. Flinn IW , Grever MR . Chronic lymphocytic leukemia . Cancer Treat Rev . 1996;22:1–13
  42. Rai KR , Peterson BL , Appelbaum FR , Kolitz J , Elias L , Shepherd L , et al.   Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N Engl J Med . 2000;343:1750–1757
  43. Dillman RO , Mick R , McIntyre OR . Pentostatin in chronic lymphocytic leukemia (A phase II trial of Cancer and Leukemia Group B) . J Clin Oncol . 1989;7:433–438
  44. Johnson SA , Catovsky D , Child JA , Newland AC , Milligan DW , Janmohamed R . Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia . Invest New Drugs . 1998;16:155–160
  45. Dearden CE , Matutes E , Catovsky D . Clinical overview of pentostatin (Nipent) use in lymphoid malignancies . Semin Oncol . 2000;27:22–26
  46. Weiss MA , Maslak PG , Jurcic JG , Scheinberg DA , Aliff TB , Lamanna N , et al.   Pentostatin and cyclophosphamide (An effective new regimen in previously treated patients with chronic lymphocytic leukemia) . J Clin Oncol . 2003;21:1278–1284
  47. Oken MM , Lee S , Kay NE , Knospe W , Cassileth PA . Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia (A phase I/II study by the Eastern Cooperative Oncology Group study E1488) . Leuk Lymphoma . 2004;45:79–84
  48. Di Bella N , Reynolds C , Faragher D , Muscato J , Boehm KA , Asmar L . An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, stage III or IV, low-grade non-Hodgkin lymphoma . Cancer . 2005;103:978–984
  49. Dimopoulos MA , Kyle RA , Anagnostopoulos A , Treon SP . Diagnosis and management of Waldenstrom’s macroglobulinemia . J Clin Oncol . 2005;23:1564–1577
  50. Waldenstrom J . Incipient myelomatosis of “essential” hyperglobulinemia with fibrinogenopenia (A new syndrome) . Acta Med Scand . 1944;117:216–222
  51. Lin P , Medeiros LJ . Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (An evolving concept) . Adv Anat Pathol . 2005;12:246–255
  52. Gertz MA . Waldenstrom macroglobulinemia (A review of therapy) . Am J Hematol . 2005;79:147–157
  53. Weber DM , Dimopoulos MA , Delasalle K , Rankin K , Gavino M , Alexanian R . 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom’s macroglobulinemia . Semin Oncol . 2003;30:243–247
  54. Kantarjian HM , Alexanian R , Koller CA , Kurzrock R , Keating MJ . Fludarabine therapy in macroglobulinemic lymphoma . Blood . 1990;75:1928–1931
  55. Dhodapkar MV , Jacobson JL , Gertz MA , Rivkin SE , Roodman GD , Tuscano JM , et al.   Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia (Results of United States intergroup trial (Southwest Oncology Group S9003)) . Blood . 2001;98:41–48
  56. Leblond V , Levy V , Maloisel F , Cazin B , Fermand JP , Harousseau JL , et al.   Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease . Blood . 2001;98:2640–2644
  57. Fenchel K , Wijermans P , Mitrou PS , Hoelzer D , Bergmann L . Fludarabine is an effective agent in immunocytic lymphoma . Onkologie . 1994;17:508–513
  58. Bjorkholm M , Celsing F , Runarsson G , Waldenstrom J . Successful intravenous immunoglobulin therapy for severe and persistent astrovirus gastroenteritis after fludarabine treatment in a patient with Waldenstrom’s macroglobulinemia . Int J Hematol . 1995;62:117–120
  59. Costa P , Luzzati R , Nicolato A , Perboni G , Scalzini A , Lazzarini L , et al.   Cryptococcal meningitis and intracranial tuberculoma in a patient with Waldenstrom’s macroglobulinemia treated with fludarabine . Leuk Lymphoma . 1998;28:617–620
  60. Dimopoulos MA , O’Brien S , Kantarjian H , Estey EE , Keating MJ , Alexanian R . Treatment of Waldenstrom’s macroglobulinemia with nucleoside analogues . Leuk Lymphoma . 1993;11(suppl 2):105–108
  61. Liu ES , Burian C , Miller WE , Saven A . Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia . Br J Haematol . 1998;103:690–695
  62. Hellmann A , Lewandowski K , Zaucha JM , Bieniaszewska M , Halaburda K , Robak T . Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom’s macroglobulinemia . Eur J Haematol . 1999;63:35–41
  63. Betticher DC , Hsu Schmitz SF , Ratschiller D , von Rohr A , Egger T , Pugin P , et al.  Swiss Group for Clinical Cancer Research (SAKK)   Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenstrom’s macroglobulinaemia . Br J Haematol . 1997;99:358–363
  64. Bryson HM , Sorkin EM . Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies . Drugs . 1993;46:872–894
  65. Van Den Neste E , Louviaux I , Michaux JL , Delannoy A , Michaux L , Hagemeijer A , et al.   Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine . Br J Haematol . 1999;105:268–270
  66. Van Den Neste E , Delannoy A , Feremans W , Ferrant A , Michaux L . Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′-deoxyadenosine treatment . Leuk Lymphoma . 2001;40:541–550
  67. Tetreault SA , Saven A . Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia . Leuk Lymphoma . 2000;37:125–130
  68. Weber DM , Gavino M , Huh Y . Phenotypic and clinical evidence supports rituximab for Waldenstrom’s macroglobulinemia . Blood . 1999;94:125a; (abstr 551)
  69. Foran JM , Rohatiner AZ , Cunningham D , Popescu RA , Solal-Celigny P , Ghielmini M , et al.   European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma . J Clin Oncol . 2000;18:317–324
  70. Treon SP , Agus TB , Link B , Rodrigues G , Molina A , Lacy MQ , et al.   CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom’s macroglobulinemia . J Immunother . 2001;24:272–279
  71. Dimopoulos MA , Zervas C , Zomas A , Kiamouris C , Viniou NA , Grigoraki V , et al.   Treatment of Waldenstrom’s macroglobulinemia with rituximab . J Clin Oncol . 2002;20:2327–2333
  72. Treon SP , Emmanouilides C , Kimby E , Kelliher A , Preffer F , Branagan AR , et al.   Extended rituximab therapy in Waldenstrom’s macroglobulinemia . Ann Oncol . 2005;16:132–138
  73. Gertz MA , Rue M , Blood E , Kaminer LS , Vesole DH , Greipp PR . Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM) (An Eastern Cooperative Oncology Group Study (E3A98)) . Leuk Lymphoma . 2004;45:2047–2055
  74. Treon SP , Branagan AR , Wasi P . In: Combination therapy with rituximab and fludarabine in Waldenstrom’s macroglobulinemia . 2004;p. 57; 3rd International Workshop on Waldenstrom’s Macroglobulinemia. Paris, France, October 7-10,
  75. Riddell S , Johnston JB , Rayner HL , Israels LG . Response of Waldenstrom’s macroglobulinemia to pentostatin (2′-deoxycoformycin) . Cancer Treat Rep . 1986;70:546–548
  76. Lamanna N , Kalaycio M , Maslak PG , Jurcic JG , Scheinberg DA , Gencarelli AN , et al.   Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms . Blood . 2004;104:950a; (abstr)
  77. Hensel M , Krasniqi F , Villabos M , Kornacker M , Ho AD . Pentostatin and cylcophosphamide followed by maintenance therapy with rituximab for previously treated patients with B-cell chronic lymphocytic leukaemia, and Walendstroem’s macroglobulinemia . Blood . 2003;102:404a; (abstr)
  78. Desikan R , Dhodapkar M , Siegel D , Fassas A , Singh J , Singhal S , et al.   High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom’s macroglobulinaemia . Br J Haematol . 1999;105:993–996
  79. Anagnostopoulos A , Dimopoulos MA , Aleman A , Weber D , Alexanian R , Champlin R , et al.   High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom’s macroglobulinemia . Bone Marrow Transplant . 2001;27:1027–1029
  80. Tournilhac O , Leblond V , Tabrizi R , Gressin R , Senecal D , Milpied N , et al.   Transplantation in Waldenstrom’s macroglobulinemia—The French experience . Semin Oncol . 2003;30:291–296
  81. Dreger P , Stilgenbauer S , Seyfarth B . In: Autologous and allogeneic stem cell transplantation for treatment of Waldenstrom’s macroglobulinemia . 2004;p. 70; 3rd International Workshop on Waldenstrom’s Macroglobulinemia. Paris, France, October 7-10
  82. Fassas A , Dhodapkar M , McCoy J . In: Management of Waldenstrom’s macroglobulinemia in the pre-rituximab era (Update on US Intergroup Trial S9003 and the Arkansas autotransplant experience) . 2004;p. 59; 3rd International Workshop on Waldenstrom’s Macroglobulinemia. Paris, France, October 7-10
  83. Leo E , Scheuer L , Schmidt-Wolf IG , Kerowgan M , Schmitt C , Leo A , et al.   Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma . Eur J Haematol . 2004;73:251–257
  84. Keating MJ , Kantarjian H , Talpaz M , Redman J , Koller C , Barlogie B , et al.   Fludarabine (A new agent with major activity against chronic lymphocytic leukemia) . Blood . 1989;74:19–25
  85. Montillo M , Tedeschi A , O’Brien S , Di Raimondo F , Lerner S , Ferrajoli A , et al.   Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia . Cancer . 2003;97:114–120
  86. O’Brien SM , Kantarjian HM , Cortes J , Beran M , Koller CA , Giles FJ , et al.   Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia . J Clin Oncol . 2001;19:1414–1420
  87. Drapkin R , Di Bella NJ , Faragher DC , Harden E , Matei C , Hyman W , et al.   Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin’s lymphoma (An effective and minimally toxic regimen) . Clin Lymphoma . 2003;4:169–175
  88. Czuczman MS , Koryzna A , Mohr A , Stewart C , Donohue K , Blumenson L , et al.   Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma . J Clin Oncol . 2005;23:694–704
  89. Wierda W , O’Brien S , Wen S , Faderl S , Garcia-Manero G , Thomas D , et al.   Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4070–4078
  90. Keating MJ , O’Brien S , Albitar M , Lerner S , Plunkett W , Giles F , et al.   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4079–4088
  91. Robak T , Blonski JZ , Gora-Tybor J , Kasznicki M , Dwilewicz-Trojaczek J , Tomaszewska A , et al.   Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia (An early report of prospective randomized study) . Blood . 2004;104:337a; (abstr)
  92. Hensel M , Villalobos M , Kornacker M , Krasniqi F , Ho AD . Pentostatin/cyclophosphamide with or without rituximab (An effective regimen for patients with Waldenstrom’s macroglobulinemia/lymphoplasmacytic lymphoma) . Clin Lymphoma Myeloma . 2005;6:131–135

PII: S0037-1963(05)00262-3

doi: 10.1053/j.seminhematol.2005.12.005

Seminars in Hematology
Volume 43 , Pages S2-S10 , April 2006

Article Tools